SAN DIEGO--Sleep product manufacturer ResMed announced last week that its board of directors has unanimously approved a succession plan for executive management of the company.
Effective Jan. 1, Kieran T. Gallahue will be promoted to CEO and will join the board of directors. Gallahue will succeed Dr. Peter C. Farrell, the company's founder, who will continue as executive chairman of the board until June 30, 2008, when he will become non-executive chairman.
"Since joining ResMed in 2003, Kieran has demonstrated strong leadership qualities," said Farrell. "He has been instrumental in improving our operational execution, targeting our research and development efforts, focusing our commercial teams to better serve patients and customers, while strengthening the depth of our management." Gallahue is "the right person to succeed me," Farrell added.
"Since founding the company in 1989, I have been passionate about the need to increase awareness of sleep-disordered breathing among both the public and the medical community, as well as the need to increase understanding of the deleterious consequences of the disease if left untreated," Farrell continued. "As chairman, I intend to remain significantly engaged in the company's mission and strategy."
"I am excited about the opportunities ahead of us--a vast untapped market, market-leading technology and a world class team of employees," Gallahue said.
Gallahue joined ResMed in January 2003 as president and COO of the Americas, and in September 2004 was named president and COO-ResMed Global. Before joining the company, Gallahue was president of Nanogen, a San Diego-based DNA research and medical diagnostics company. Earlier in his career, he worked for Instrumentation Laboratory, Procter & Gamble and General Electric.
